{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:18:18Z","timestamp":1780604298065,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clinthera.2018.12.015","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T20:23:31Z","timestamp":1551731011000},"page":"249-260.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis"],"prefix":"10.1016","volume":"41","author":[{"given":"Patrick","family":"Vermersch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pfleger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Alonso-Magdalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dangond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.12.015_bib1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2018.12.015_bib2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2018.12.015_bib3","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2018.12.015_bib4","first-page":"2023","article-title":"Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS","volume":"260","author":"Cohen","year":"2013","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.clinthera.2018.12.015_bib5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/01.wco.0000413319.87092.19","article-title":"Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs","volume":"25","author":"Miller","year":"2012","journal-title":"Curr Opin Neurol"},{"issue":"Sppl 1","key":"10.1016\/j.clinthera.2018.12.015_bib6","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0022-510X(11)70006-5","article-title":"Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis","volume":"311","author":"Sorensen","year":"2011","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.clinthera.2018.12.015_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ane.12712","article-title":"Safety concerns and risk management of multiple sclerosis therapies","volume":"136","author":"Soelberg Sorensen","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clinthera.2018.12.015_bib8","series-title":"Benefit-risk Methodology Project. Work Package 2 Report: Applicability of Current Tools and Processes for Regulatory Benefit-Risk Assessment","author":"EMA","year":"2010"},{"key":"10.1016\/j.clinthera.2018.12.015_bib9","series-title":"Benefit-risk Methodology Project. Work Package 4 Report: Benefit-Risk Tools and Processes","author":"EMA","year":"2012"},{"key":"10.1016\/j.clinthera.2018.12.015_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/pds.3958","article-title":"Recommendations for benefit\u2013risk assessment methodologies and visual representations","volume":"25","author":"Hughes","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2018.12.015_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.pec.2016.12.028","article-title":"Interventions to support risk and benefit understanding of disease-modifying drugs in Multiple Sclerosis patients: a systematic review","volume":"100","author":"Reen","year":"2017","journal-title":"Patient Educ Couns"},{"issue":"4","key":"10.1016\/j.clinthera.2018.12.015_bib12","first-page":"CD008757","article-title":"Information provision for people with multiple sclerosis","author":"Kopke","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2018.12.015_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458516671204","article-title":"Shared decision-making in multiple sclerosis","volume":"23","author":"Colligan","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.clinthera.2018.12.015_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14737175.2016.1217155","article-title":"Perception of risk and shared decision making process in multiple sclerosis","volume":"17","author":"Cocco","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2018.12.015_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0272989X14551638","article-title":"Where is the evidence? A systematic review of shared decision making and patient outcomes","volume":"35","author":"Shay","year":"2015","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2018.12.015_bib16","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/cpt.507","article-title":"Benefit-risk analysis for decision-making: an approach","volume":"100","author":"Raju","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2018.12.015_bib17","first-page":"676","article-title":"Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England","volume":"21","author":"Hettle","year":"2018","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clinthera.2018.12.015_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2018.12.015_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fimmu.2018.00138","article-title":"Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis upatients treated with immunomodulatory therapies: a bird's eye view","volume":"9","author":"Mills","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2018.12.015_bib20","series-title":"Benefit-risk Methodology Project. Work Package 4 Report: Benefit-Risk Tools and Processes","author":"EMA","year":"2012"},{"issue":"5","key":"10.1016\/j.clinthera.2018.12.015_bib21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A\u00a0placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.12.015_bib22","unstructured":"Tysabri US PI. Available from: http:\/\/www.tysabri.com\/prescribingInfo. Accessed Nov 2015."},{"issue":"9","key":"10.1016\/j.clinthera.2018.12.015_bib23","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A\u00a0randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.12.015_bib24","unstructured":"Tysabri EPAR. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000603\/WC500044688.pdf. Accessed Nov 2015."},{"issue":"5","key":"10.1016\/j.clinthera.2018.12.015_bib25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A\u00a0placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.12.015_bib26","unstructured":"Gilenya EPAR. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Public_assessment_report\/human\/002202\/WC500104529.pdf. Accessed Nov 2015."},{"key":"10.1016\/j.clinthera.2018.12.015_bib27","unstructured":"Lemtrada US PI. Available from: http:\/\/products.sanofi.us\/Lemtrada\/Lemtrada.pdf. Accessed Nov 2015."},{"issue":"9856","key":"10.1016\/j.clinthera.2018.12.015_bib28","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.clinthera.2018.12.015_bib29","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2018.12.015_bib30","unstructured":"Lemtrada EPAR. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Public_assessment_report\/human\/003718\/WC500150522.pdf. Accessed Nov 2015."},{"issue":"12","key":"10.1016\/j.clinthera.2018.12.015_bib31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.clinthera.2018.12.015_bib32","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.12.015_bib33","unstructured":"Tecfidera US PI. Available from: http:\/\/www.tecfidera.com\/pdfs\/full-prescribing-information.pdf. Accessed Nov 2015."},{"key":"10.1016\/j.clinthera.2018.12.015_bib34","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.80.7_supplement.P07.097","article-title":"Clinical efficacy of BG-12 (dimethyl fumarate) in relapsing\u2013remitting multiple sclerosis (RRMS): an integrated analysis of the Phase 3 DEFINE and CONFIRM Studies","author":"Fox","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2018.12.015_bib35","unstructured":"Tecfidera EPAR. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002601\/WC500162070.pdf. Accessed Nov 2015."},{"key":"10.1016\/j.clinthera.2018.12.015_bib36","unstructured":"Aubagio EU SmPC. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/28533. Accessed Nov 2015."},{"key":"10.1016\/j.clinthera.2018.12.015_bib37","unstructured":"Aubagio US PI."},{"issue":"3","key":"10.1016\/j.clinthera.2018.12.015_bib38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1016\/j.clinthera.2018.12.015_bib39","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.12.015_bib40","unstructured":"Aubagio EPAR. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002514\/WC500148684.pdf. Accessed Nov 2015."},{"issue":"6","key":"10.1016\/j.clinthera.2018.12.015_bib41","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","article-title":"A\u00a0Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses","volume":"66","author":"O'Connor","year":"2006","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2018.12.015_bib42","first-page":"S79","article-title":"Medication gaps in disease-modifying drug therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database","volume":"255","author":"Al-Sabbagh","year":"2008","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.clinthera.2018.12.015_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","article-title":"Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study","volume":"30","author":"Steinberg","year":"2010","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.clinthera.2018.12.015_bib44","first-page":"601","article-title":"Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US","volume":"15","author":"Ivanova","year":"2012","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.clinthera.2018.12.015_bib45","first-page":"739","article-title":"The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate","volume":"14","author":"Oleen-Burkey","year":"2011","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.clinthera.2018.12.015_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"Tan","year":"2011","journal-title":"Adv Ther"},{"issue":"20","key":"10.1016\/j.clinthera.2018.12.015_bib47","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.12.015_bib48","unstructured":"Panzara, M.A. Natalizumab safety. Available from: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006-4208S1-01-02-%20Biogen-Panzara.pdf."},{"key":"10.1016\/j.clinthera.2018.12.015_bib49","unstructured":"Tysabri FDA Assessment report. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/125104s000_Natalizumab_Medr_P3.pdf."},{"key":"10.1016\/j.clinthera.2018.12.015_bib50","unstructured":"Gilenya EU SmPC. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/24443. Accessed Nov 2015."},{"issue":"6","key":"10.1016\/j.clinthera.2018.12.015_bib51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2018.12.015_bib52","unstructured":"Gilenya US PI. Available from: https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gilenya.pdf. Accessed Nov 2015."},{"key":"10.1016\/j.clinthera.2018.12.015_bib53","unstructured":"Gilenya CDER review. Application number 22-527. August 26, 2010."},{"key":"10.1016\/j.clinthera.2018.12.015_bib54","unstructured":"Gilenya RMP. Fingolimod EU Safety Risk Management Plan (EMA\/357270\/2012). 18 June 2012."},{"issue":"1","key":"10.1016\/j.clinthera.2018.12.015_bib55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use","volume":"8","author":"Havrdova","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.clinthera.2018.12.015_bib56","unstructured":"Lemtrada FDA background package for alemtuzumab (BLA 103948\u22165139). November 2013."},{"issue":"9","key":"10.1016\/j.clinthera.2018.12.015_bib57","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1352458515614092","article-title":"Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort","volume":"22","author":"Willis","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.clinthera.2018.12.015_bib58","unstructured":"Tecfidera EU SmPC. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/28593. Accessed Nov 2015."},{"key":"10.1016\/j.clinthera.2018.12.015_bib59","unstructured":"Tecfidera RMP. BG00012 EU Risk Management Plan. March 2013 (Version 5)."},{"key":"10.1016\/j.clinthera.2018.12.015_bib60","unstructured":"Aubagio RMP. EU Safety Risk Management Plan. March 2015."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819300025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819300025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:53Z","timestamp":1758962993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819300025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0149291819300025"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.12.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}